Health Check is renowned biotech journo Tim Boreham’s NEW daily wrap covering morning movers and shakers of note in the ASX Healthcare sector, Monday through Thursday.
- From the weeds of despair, buds of earnings hope are emerging at Cann Group
- Opthea proves it reliably can manufacture its advanced drug candidate for the common eye disease wet age-related macular degeneration.
- Singular Health sells a non-core asset and strikes a rent-free deal
Struggling medical pot pioneer Cann Group (ASX:CAN) says it expects to return to underlying earnings profitability this year, having posted a $13.2 million loss in the 2023-24 stanza.
The company also expects to be cash-flow positive in 2025-26.
In a presentation to the Pitt Street Research life sciences conference in Sydney today, the company has outlined a plan to increase capacity at its flagship Mildura facility to the maximum 10,000…
